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Lung cancer remains the leading cause of cancer-related death 
throughout the world.1 Fortunately, outstanding development 
in cancer genomics and molecular targeted therapy has allowed 
targeted therapy that includes treatment optimization based on 
molecular testing and target mutation, especially in adenocarci-
noma. Specifically, the great success of the epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) follow-
ing the discovery of somatic EGFR gene mutation has raised 
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hope that a targeted therapy will improve survival and quality 
of life for lung cancer patients.2-4 In this context, genetic analy-
ses of various molecular markers in tumor tissue have become 
standard laboratory tests for the clinical management of lung 
cancers.
In 2007, the anaplastic lymphoma kinase (ALK) gene rear-
rangement creating an in-frame fusion protein between echino-
derm microtubule-associated protein-like 4 (EML4) and ALK 
was described in non-small cell lung carcinoma (NSCLC) by 
Soda et al.5 The presence of ALK gene rearrangement in lung 
adenocarcinomas is the best predictor of response to crizotinib, 
an ALK tyrosine kinase inhibitor.6-8 The Food and Drug Ad-
ministration (FDA) approved crizotinib with a companion diag-
nostic fluorescence in situ hybridization (FISH) test (Vysis, Ab-
bott Molecular Inc., Des Plaines, IL, USA) for ALK-rearranged 
NSCLC. However, the prevalence of the ALK fusion is low, at 
around 5% in various previous studies.6,8-13 Thus, accurate pa-
tient identification is crucial for successful treatment using the 
ALK inhibitor and the proposal of a standard guideline suitable 
for the Korean medical community is also needed.
Herein, we reviewed several publications related with consen-
sus opinions and recommendations for molecular testing in lung 
cancer, including ALK testing, and propose a guideline recom-
mendation for ALK testing approved by the Cardiopulmonary 
Pathology Study Group of the Korean Society of Pathologists 
(Table 1).
PATIENT ELIGIBILITY
Clinical characteristics associated with the ALK gene rear-
rangement are known to be adenocarcinoma histology, never/
light smoking history, and younger age.6,13-15 However, not all 
ALK-rearranged patients demonstrate these characteristics. ALK 
fusion has also been detected in older patients (over 70 years old) 
with a smoking history, and in patients with squamous cell car-
cinoma.12,16 Therefore, clinical characteristics alone are not the 
determinant of ALK testing. Guidelines from the College of 
American Pathologists (CAP), the International Association for 
the Study of Lung Cancer (IASLC), and the Association for Mo-
lecular Pathology (AMP) also state that clinical characteristics 
(age, sex, ethnicity, smoking history, etc.) are not sufficiently 
sensitive or specific to be used to select or exclude patients for 
treatment or testing for ALK gene rearrangement.17
Recent published guidelines recommend histological type as 
the most important factor for determining whether ALK test-
ing should be performed. Patients who are diagnosed with ade-
nocarcinoma, large cell carcinoma, or non-small cell carcinoma 
with an adenocarcinoma component are recommended for ALK 
testing.17,18 Thus, accurate histological diagnosis is the first step 
for molecular testing. Pathologists should try to further classify 
poorly differentiated NSCLCs into more specific types using 
immunohistochemistry (IHC), such as thyroid transcription 
factor-1, napsin A, p63, p40, and cytokeratin5/6.19-24 There 
have been a few reports about squamous cell carcinoma harbor-
ing ALK gene rearrangement, but the frequency is very low.6,16 
Table 1. Summary of ALK testing guideline recommendations
                                                                      Recommendation
Patient eligibility Histologic type is the most important factor: patients diagnosed with adenocarcinoma, large cell carcinoma or non-small cell 
   carcinoma with adenocarcinoma component should be tested for ALK rearrangement.
Clinical criteria might be considered, when adenocarcinoma component cannot be completely excluded.
Specimen type Histological and cytological specimens are both acceptable.
Either primary tumors or metastatic lesions are equally suitable.
In cases with multiple, synchronous primary lung adenocarcinomas, each tumor may be tested.
Sample selection A minimum of 50-100 assessable tumor cells are required for ALK FISH test.
ALK IHC can be performed as long as there are at least a few clusters of viable tumor cells.
Sample processing Fixative: 10% neutral-buffered formalin, immediately after the sample is removed from the patient.
Fixation time: from 6 to 48 hours.
Avoid decalcified tissue.
Routine preparation for cytology is acceptable, if fully validated.
Diagnostic method FISH is a companion diagnostic test for detection of ALK rearrangement.
IHC can be a potential screening method with high sensitive detection method.
RT-PCR is highly sensitive but not recommended as a first-line diagnostic method for determining ALK fusion status.
The pathologist should consider the pros and cons of each method and combination of more than one technique may be 
   useful in equivocal cases.
Reporting format Patients and sample information, type of detection method, results of the test, comments.
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; RT-PCR, reverse transcriptase-polymerase chain re-
action.
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Thus, the CAP-IASLC-AMP guideline does not recommend 
ALK testing in lung cancer cases without any adenocarcinoma 
component, such as pure squamous cell carcinomas, pure small 
cell carcinomas, or large cell carcinomas lacking any IHC evi-
dence of adenocarcinoma differentiation.17
Actually, about two-thirds of lung cancer patients present 
with advanced stage at the time of diagnosis, and small biopsies 
or cytology specimens are the only available samples for diagno-
sis and molecular testing. In these cases, histological sub-typing 
may not be always feasible, the biopsy or cytology specimens 
may not be representative of the whole tumor, and any adeno-
carcinoma component cannot be completely excluded. For these 
cases, ALK testing is recommended and the clinical features, 
such as young age and/or lack of smoking history, may be used 
to select patients for testing.17
SPECIMEN TYPE AND PROCESSING FOR  
ALK TESTING
Specimen type
Various biopsy specimens obtained by different techniques in-
cluding endoscopic biopsies, core-needle biopsies, biopsies guid-
ed by endobronchial ultrasound (EBUS) or endoscopic esopha-
geal ultrasound, mediastinoscopy, and thoracotomy can be used 
for ALK testing. Recent studies have shown that cytology speci-
mens are suitable for ALK testing, and that the results are high-
ly concordant with those of corresponding histological speci-
mens, thus cytology specimens such as EBUS-guided fine-needle 
aspiration (FNA), transthoracic FNA, bronchial secretions or 
brushes, bronchoalveolar lavages, and pleural effusions can be 
used for ALK testing.25-28 Thus, both histological and cytologi-
cal specimens are acceptable for ALK testing, if appropriately 
processed and validated.
Tumor tissues from either primary tumors or metastatic le-
sions are equally suitable for ALK testing according to biopsy 
accessibility. Although discordance in ALK status between pri-
mary and metastatic disease has been reported,29 data are insuf-
ficient regarding which one is better for ALK testing.17 For pa-
tients with multiple, synchronous primary lung adenocarcino-
mas, each tumor may be tested. However, testing of multiple 
different areas within a single tumor is not necessary, because 
heterogeneity of ALK gene status does not seem to be related to 
the presence of a different histological pattern or biology, but is 
more likely due to technical problems.17 
Sample selection
A sufficient number of tumor cells are crucial for successful 
molecular testing. The number of tumor cells required for IHC 
assessment of ALK protein remains undefined, as IHC can be 
performed as long as there are at least a few clusters of viable tu-
mor cells. Regarding ALK FISH, a minimum of 50 to 100 as-
sessable tumor cells are required. Unlike EGFR mutation test-
ing, cells are analyzed individually, so tumor percentage is not 
as critical. However, it is necessary to choose slides or regions of 
slides in which the tumor cells do not overlap, and to distin-
guish them from the adjacent non-neoplastic cells. If the tumor 
component is very focal within the sample, it is recommended 
that the area examined be marked on the slide so that it may be 
readily identifiable under a dark field fluorescence microscope. 
In this step, the pathologist has the responsibility to determine 
if the selected sample contains a sufficient number and quality 
of tumor cells to ensure the quality of the analysis.
Sample processing
Formalin-fixed, paraffin-embedded (FFPE) tissues are routine-
ly used for molecular testing. The diagnostic kits for ALK test-
ing were developed and validated only on FFPE histological 
samples.18 The first and most important step in tissue processing 
is immediate fixation, preferably within one hour after the sam-
ple is removed from the patient.30,31 It is widely recognized that 
10% neutral-buffered formalin is ideal for preparing FFPE sam-
ples, whereas the optimal fixation time ranges from six to 48 
hours.18,31-33 Specimens treated with decalcifying solution (e.g., 
bone biopsy) are usually suboptimal for molecular studies, be-
cause the solution may interfere with IHC and can frequently 
compromise FISH testing, so the reliability of molecular testing 
is reduced.
Regarding cytological specimens, most sample types, includ-
ing conventional smears, cytospins, or liquid-based preparations 
(e.g., ThinPrep, Hologic, or SurePath, BD Diagnostics) regard-
less of fixation type (air-dried and alcohol-based fixatives) can be 
used for ALK testing. Cytology specimens should be fixed im-
mediately by the usual alcohol-based methods. For FISH analy-
sis, the use of adhesive-coated or positively charged slides in 
lung cytology is recommended, as these slides improve the ad-
herence of the cells. FISH works equally well on unstained spec-
imens as well as those processed with Papanicolaou, hematoxy-
lin, or a modified Giemsa stain, and a separate procedure is not 
usually required. However, in case of a modified Giemsa stain, 
de-staining with an acid-alcohol technique is recommended be-
fore FISH analysis.25 Cell blocks are regarded as appropriate for 
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molecular testing and can be handled in the same way as histo-
logical FFPE specimens. 
DIAGNOSTIC METHODS FOR ALK GENE 
REARRANGEMENT
Several methods are currently available to assess ALK gene 
rearrangement, including FISH, IHC, and reverse transcriptase-
polymerase chain reaction (RT-PCR).
Fluorescence in situ hybridization
FISH is currently the standard method to detect ALK rear-
rangements because it was used previously in clinical trials, and 
is the only test correlated with clinical response. The FDA has 
approved crizotinib with a companion diagnostic FISH test for 
ALK-rearranged NSCLC using the certified commercial kit, 
Abbott Vysis (ALK Break Apart FISH Probe Kit, Abbott Mo-
lecular Inc.). The kit includes red (3’) and green (5’)-colored 
break-apart probes, which overlap in a fused signal without 
ALK gene rearrangement (Fig. 1A). Although the break-apart 
FISH assay requires experience for interpretation, patience, high 
cost, and technical expertise, this assay is highly sensitive and 
specific for the detection of ALK gene rearrangement regardless 
of ALK fusion partners.
Interpretation should be performed in areas of the slide with 
good signal, in which at least 50% of all nuclei are easily analyz-
able, with minimal background or nuclear fluorescent “noise.” 
Areas where the borders of individual nuclei are not clearly 
identifiable and/or high cell density causes excessive nuclear 
overlap are easily misinterpreted, and should be avoided. Crite-
ria that must be met for a break-apart FISH assay to be consid-
ered positive for ALK rearrangement include: at least 50 cells 
counted and at least 15% of the counted cells demonstrating 
separated green and red signals by at least two signal diameters 
(Fig. 1B), and/or an isolated red signal (Fig. 1C).34 There have 
been several reports in which a few cases showed “borderline” 
ALK FISH positivity that approached the 15% cutoff point or 
less than two signal diameter distances. These cases were re-
garded as negative with the current criteria and suggest alterna-
tive ALK diagnostic techniques and/or an assessment of their 
response to ALK inhibitors would be required. There are also 
rare instances when FISH showed atypical signal patterns, such 
as for an isolated 5’ signal that does not fulfill current positive 
criteria. Such unusual patterns require confirmation of ALK sta-
tus using a different secondary assay or examination of the ef-
fects of crizotinib therapy.
Immunohistochemistry
ALK protein represents a potential marker for indicating ALK 
gene rearrangement, and immunohistochemical detection of 
ALK protein can be a rapid screening method with low cost for 
detection of ALK-rearranged NSCLC. When the ALK1 anti-
body, which has been used for the diagnosis of anaplastic large 
cell lymphoma (ALCL) is applied, detection of ALK protein in 
NSCLCs is difficult because the protein expression level is usual-
ly lower in NSCLCs than in ALCL.35 Therefore, several factors 
including antigen retrieval, primary antibodies with high affinity 
and sufficient concentration, incubation time and temperature, 
and strong amplification of the signal should be applied to im-
prove the sensitivity of ALK IHC. There are three ALK antibod-
Fig. 1. Break-apart fluorescence in situ hybridization (FISH) patterns. Representative FISH images of anaplastic lymphoma kinase (ALK)-neg-
ative (A) and ALK-rearranged tumors (B, C) are demonstrated. Tumors are considered ALK-positive when green and red signals are separat-
ed by at least two signal diameters (B) or a single red signal without a corresponding green signal, in addition to fused and/or break-apart sig-
nals (C).
A B C
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ies (ALK1, 5A4, and D5F3) that have been studied in depth for 
NSCLC. D5F3 and 5A4 appeared to be both more sensitive and 
more specific than the ALK1 antibody.35-38 For a detection sys-
tem, there are various systems with a substantial degree of signal 
amplification (Leica/Novocastra Novolink, Dako Advance, Tyra-
mide, Envision+, Ventana i-view). Using highly sensitive detec-
tion methods in combination with high affinity antibodies, IHC 
can effectively detect ALK fusion protein with high sensitivity 
and specificity. However, so far, there is no qualified guideline for 
the selection of primary antibodies or the detection system.
There are still several considerations regarding the use of 
ALK IHC as a screening method for ALK rearrangement. First 
of all, there is no accepted standard criterion for IHC interpreta-
tion. IHC scoring has been proposed by several publications, 
including a representatively binary system (positive/negative) 
9,37,39,40 and a scoring system in the range of 0 to 3 by signal in-
tensity and percentage (Fig. 2).11,35,36,38,41-44 As a screening tool, 
IHC score is an important criterion for the selection of patients 
for ALK FISH testing or crizotinib therapy. Paik et al.11 showed 
good correlations between IHC score and FISH results: cases as-
signed an ALK IHC score of 3 showed FISH-positivity, while 
ALK IHC scores of 0 and 1 showed FISH-negativity. However, 
there are arguments that a four-tiered scoring system creates 
higher inter-observer variability, so a binary system is more than 
clear cut for the selection of ALK-positive patients.44 Thus, we 
recommend that tumors that are positive for ALK IHC, either 
weakly or strongly, should still be referred to FISH analysis for 
confirmation of a rearrangement, regardless of primary antibody 
or detection system.
Another consideration is the lack of clinical validation for 
crizotinib treatment in ALK IHC positive and FISH negative 
cases. Although there was a report that showed a FISH nega-
tive, IHC positive patient who showed better response to crizo-
tinib,45 this single instance is insufficient to develop a specific 
recommendation regarding the use of ALK IHC as a sole deter-
minant of ALK TKI therapy.
A B
C D
Fig. 2. Anaplastic lymphoma kinase protein expression by immunohistochemistry with a 0-3 intensity-based scoring system. Representative 
images of score 3 (A), 2 (B), 1 (C), and 0 (D) are displayed. 
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If the IHC method is eventually proven to be accurate in de-
tecting ALK rearrangements and variability, and interpretation 
can be standardized, IHC assays hold the potential to facilitate 
the routine identification of ALK-rearranged lung adenocarci-
noma. Many studies have investigated and reported the high 
concordance between IHC and FISH results.11,35,39-44,46,47 The 
CAP-IASLC-AMP guideline also recommends that a properly 
validated IHC method be used as a screening modality, and that 
tumors that fail to demonstrate ALK immunoreactivity with a 
sensitive IHC method need not be tested for ALK rearrange-
ment by FISH.17
Reverse transcriptase-polymerase chain reaction
ALK rearrangement generates a unique sequence and the PCR 
primer that hybridizes with the fusion transcript is responsible 
for the high sensitivity of the RT-PCR test.48-50 However, RT-
PCR requires ALK fusion variants to be known so that primers 
to all variants should be included in the reaction.51-53 Although, 
despite an ever-expanding list of ALK fusion variants, all the re-
ported variants require skillful application. In addition, the ma-
jority of current ALK fusion variants were detected by RT-PCR 
in fresh frozen tumor tissue. However, in daily clinical practice, 
most of the tumor tissues available for molecular profiling are 
FFPE samples,53 where the integrity of RNAs is likely to be 
greatly compromised compared with fresh frozen tissue. Thus, at 
the present time, RT-PCR is not recommended as a first-line di-
agnostic method for determining ALK fusion status.
DIAGNOSTIC ALGORITHM
Based on the advantages and characteristics of individual 
methods for detecting ALK gene status, several investigator 
groups have proposed diagnostic algorithms for ALK testing. 
11,18,36,54,55 Considering the trends that the histological types are 
usually determined by only small biopsy materials or cytological 
specimens in advanced NSCLC patients, we recommend that 
ALK rearrangement testing should be done simultaneously 
with EGFR/K-ras mutation testing for eligible patients (Fig. 3). 
We also propose that validated IHC can be used as a screening 
method to detect the ALK rearrangement and ALK FISH can 
be a confirmative method for all cases showing positive ALK 
IHC results. If the consensus between pathologists and institu-
Fig. 3. Diagnostic algorithm for molecular testing of small biopsy or cytological specimens in non-small cell lung cancer patients. LCNEC, 
large cell neuroendocrine carcinoma; SqCC, squamous cell carcinoma; ADC, adenocarcinoma; NSCLC, non-small cell lung carcinoma; 
NOS, not otherwise specified; ASC, adenosquamous carcinoma; IHC, immunohistochemistry; EGFR, epidermal growth factor receptor; 
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization. 
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tional clinicians can be established, ‘reflex molecular testing’ is 
recommended to minimize the exhaustion of small biopsy tissue 
samples for the necessary molecular tests, and to provide a rapid 
determination of the genetic characteristics of NSCLC patients.
REPORTING THE RESULTS
Molecular testing reports should contain the following infor-
mation: 1) identification of the patient including pathologic 
number, age, sex, hospital unit number, and requesting physi-
cian/department, 2) material used for the analysis including bi-
opsy site and sample source, 3) methodology used for analysis 
and the type of commercial test used, and 4) test results, ex-
pressed in terms of negativity or positivity for the rearrangement 
of the ALK gene. We recommend reporting the following de-
tails: total number of counted nuclei, percentage of the nuclei 
showing gene rearrangements (break-apart and isolated red sig-
nal), as well as atypical pattern (e.g., isolated green signal), and 
copy number gain if observed, 5) receipt day and report day, 6) 
comments, and 7) names of testing technician and correspond-
ing pathologist.
PROPOSAL FOR AN EXTERNAL QUALITY 
ASSESSMENT PROGRAM
For optimal ALK testing in NSCLC, the quality of the sam-
ple, validation status of the analytical procedure, and reliable re-
porting of the test results are crucial. There are several accessible 
external quality assessment (EQA) programs for the quality as-
sessment of molecular testing (e.g., http://lung.eqascheme.org; 
http://kras.eqascheme.org; http://www.ukneqas.org.uk; http://
www.emqn.org/emqn/schemes; http://www.quip-ringversuche.
de). At this time, no external quality control program for ALK 
testing exists. To improve the reliability of assays for detecting 
ALK positivity, as well as optimal information regarding pa-
tient selection for ALK inhibitors, further studies should be 
performed to compare and validate these different diagnostic 
assays. Quality control programs used in HER-2 testing in 
Spain, the United Kingdom, and Scandinavia would be a good 
role model.33
CONCLUSION: ROLE OF PATHOLOGISTS AND 
FUTURE PERSPECTIVES
Molecular testing for targetable mutation has emerged as the 
standard of care in the management of patients with lung ade-
nocarcinoma. Standardization and optimization of diagnostic 
molecular testing methods using clinical samples have become 
increasingly important. However, because most lung cancer pa-
tients present with an advanced tumor stage at the time of diag-
nosis, the diagnosis of lung cancer is often based on small speci-
mens from a biopsy or cytology alone. Therefore, it is important 
that the pathologists handle specimens carefully for further mo-
lecular profiling, including EGFR and ALK tests, and do their 
best to obtain rapid and accurate determination of the patients 
who are candidates for targeted therapy. Each pathology depart-
ment must fully validate the detection methods and develop a 
strategy to manage clinical samples and closely collaborate with 
clinicians. As a professional group, pathologists should take the 
lead in determining laboratory references, based on a balance 
between patient care and resource availability.
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